📊 BIXT Key Takeaways
Is Bioxytran, Inc. (BIXT) a Good Investment?
Bioxytran exhibits critical financial distress with negative stockholders equity of -$2.9M, indicating the company is technically insolvent. Revenue has collapsed 22.5% YoY to just $33.6K while operating losses continue to deteriorate, with negative operating cash flow of -$289.5K consuming cash reserves. The company faces imminent solvency risk with minimal liquid assets of $14.5K against $3.1M in liabilities and insufficient operational momentum for turnaround.
BIOXYTRAN, INC shows extremely weak fundamentals, with minimal revenue, persistent operating and net losses, and deeply negative margins that indicate the business is not close to covering its cost structure. Financial health is highly stressed due to negative equity, near-zero liquidity, very low cash, and ongoing cash burn, making the growth profile low quality and heavily dependent on external financing rather than internally generated cash flow.
Why Buy Bioxytran, Inc. Stock? BIXT Key Strengths
- Positive gross margin of 30.5% suggests underlying product economics are viable if revenue can scale
- Marginal improvement in net loss of 0.6% and diluted EPS improvement of 33.3% YoY shows minimal stabilization
- Pharmaceutical sector positioning offers potential for value creation if pipeline development succeeds
- The company is generating some revenue and maintained positive gross profit
- Net income was roughly stable year over year, indicating losses did not materially worsen
- Diluted EPS improved year over year, suggesting modest loss-per-share improvement
BIXT Stock Risks: Bioxytran, Inc. Investment Risks
- Negative stockholders equity of -$2.9M indicates technical insolvency and existential solvency risk
- Revenue base of $33.6K is critically small and declining, insufficient to support $3.1M liability structure
- Negative operating cash flow of -$289.5K with only $14.5K in cash reserves suggests runway of less than 2 weeks at current burn rate
- Current ratio of 0.00x indicates no ability to meet short-term obligations
- No insider trading activity in 90 days suggests loss of management confidence or dormant operations
- Negative stockholders' equity and liabilities far exceeding assets indicate severe balance-sheet weakness
- Cash of $14.50K versus negative operating cash flow and negative free cash flow raises going-concern and financing risk
- Revenue remains extremely small relative to operating expenses, resulting in unsustainably large operating and net losses
Key Metrics to Watch
- Monthly burn rate and cash runway until depletion
- Revenue growth rate and ability to achieve $500K+ quarterly revenue
- Stockholders equity trajectory and path to positive net worth
- Operating cash flow inflection and achievement of positive monthly cash generation
- Quarterly cash balance and operating cash burn
- Revenue growth relative to operating expense reduction
Bioxytran, Inc. (BIXT) Financial Metrics & Key Ratios
💡 AI Analyst Insight
The current ratio below 1.0x warrants monitoring of short-term liquidity.
BIXT Profit Margin, ROE & Profitability Analysis
BIXT vs Healthcare Sector: How Bioxytran, Inc. Compares
How Bioxytran, Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Bioxytran, Inc. Stock Overvalued? BIXT Valuation Analysis 2026
Based on fundamental analysis, Bioxytran, Inc. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Bioxytran, Inc. Balance Sheet: BIXT Debt, Cash & Liquidity
BIXT Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Bioxytran, Inc.'s revenue has declined by 41% over the 5-year period, indicating business contraction. The most recent EPS of $-0.02 indicates the company is currently unprofitable.
BIXT Revenue Growth, EPS Growth & YoY Performance
BIXT Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q2 2018 | $20.3K | -$115.7K | N/A |
| Q1 2018 | $7.4K | -$29.6K | N/A |
| Q3 2017 | $101.1K | $48.9K | N/A |
| Q2 2017 | $39.5K | -$163.0K | N/A |
| Q1 2017 | $7.4K | -$64.6K | N/A |
| Q3 2016 | $101.1K | -$30.1K | N/A |
| Q2 2016 | $55.6K | -$163.0K | N/A |
| Q1 2016 | $31.5K | -$39.1K | N/A |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Bioxytran, Inc. Dividends, Buybacks & Capital Allocation
BIXT SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Bioxytran, Inc. (CIK: 0001445815)
📋 Recent SEC Filings
❓ Frequently Asked Questions about BIXT
What is the AI rating for BIXT?
Bioxytran, Inc. (BIXT) has a Combined AI Rating of STRONG SELL from Claude (STRONG SELL) and ChatGPT (STRONG SELL) with 96% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are BIXT's key strengths?
Claude: Positive gross margin of 30.5% suggests underlying product economics are viable if revenue can scale. Marginal improvement in net loss of 0.6% and diluted EPS improvement of 33.3% YoY shows minimal stabilization. ChatGPT: The company is generating some revenue and maintained positive gross profit. Net income was roughly stable year over year, indicating losses did not materially worsen.
What are the risks of investing in BIXT?
Claude: Negative stockholders equity of -$2.9M indicates technical insolvency and existential solvency risk. Revenue base of $33.6K is critically small and declining, insufficient to support $3.1M liability structure. ChatGPT: Negative stockholders' equity and liabilities far exceeding assets indicate severe balance-sheet weakness. Cash of $14.50K versus negative operating cash flow and negative free cash flow raises going-concern and financing risk.
What is BIXT's revenue and growth?
Bioxytran, Inc. reported revenue of $33.6K.
Does BIXT pay dividends?
Bioxytran, Inc. does not currently pay dividends.
Where can I find BIXT SEC filings?
Official SEC filings for Bioxytran, Inc. (CIK: 0001445815) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is BIXT's EPS?
Bioxytran, Inc. has a diluted EPS of $-0.02.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is BIXT a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, Bioxytran, Inc. has a STRONG SELL rating with 96% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is BIXT stock overvalued or undervalued?
Valuation metrics for BIXT: ROE of N/A (sector avg: 15%), net margin of -4,761.0% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy BIXT stock in 2026?
Our dual AI analysis gives Bioxytran, Inc. a combined STRONG SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is BIXT's free cash flow?
Bioxytran, Inc.'s operating cash flow is $-289.5K, with capital expenditures of $87.3K. FCF margin is -1,120.5%.
How does BIXT compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin -4,761.0% (avg: 12%), ROE N/A (avg: 15%), current ratio 0.00 (avg: 2).